Cannara Biotech (LOVE) Status update summary

Strategic focus and business model

• Maintains a disciplined, growth-oriented approach, concentrating on markets with structural advantages and sustainable margins.

• Operates two major Quebec facilities with scalable production, currently at 50,000 kg and a roadmap to 100,000 kg.

• Three flagship brands (Tribal, Nugz, Orchid) drive retail success across multiple categories and price points.

• National distribution spans eight provinces, with strong shelf presence and consistent profitability (19 quarters of positive Adjusted EBITDA).

• Focuses on market discipline, low-cost scale, and consumer-first brand strategy.

Financial performance and capital allocation

• Fiscal 2025 net revenues reached CAD 108 million, with a 41% gross margin and 86% Adjusted EBITDA growth to CAD 28.1 million.

• Q1 2026 net revenues were CAD 30.1 million, up 20% year-over-year, with a 45% gross margin and record Adjusted EBITDA of CAD 8.8 million.

• Operating cash flow for fiscal 2025 was approximately CAD 20 million, with free cash flow of CAD 13.5 million.

• Balance sheet includes CAD 16.5 million in cash, CAD 53.5 million in working capital, and CAD 34 million in debt at a 5.3% average interest rate.

• Capital requirements for expansion to 100,000 kg capacity are about CAD 30 million, with high ROI and payback periods under one year per room.

Market share, growth, and competitive positioning

• National retail market share increased from 2.9% (fiscal 2024) to 4.1% (Q1 2026), with Quebec market share in the mid-teens and number one position.

• Gains are driven by disciplined SKU management, strong sell-through, and velocity, not SKU proliferation.

• Outperformed top 10 Canadian LPs in quarter-over-quarter retail sales growth, while peers declined.

• Maintains sustainable gross margins (40-45%) with potential to improve through genetics and economies of scale.

• Competitive advantages include vertical integration, proprietary genetics, and cost efficiencies in Quebec.